Blank, C.U.; Wong, D.J.; Ho, T.H.; Bauer, T.M.; Lee, C.B.; Bene-Tchaleu, F.; Zhu, J.; Zhang, X.; Cha, E.; Sznol, M.
Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors. Curr. Oncol. 2021, 28, 5466-5479.
https://doi.org/10.3390/curroncol28060455
AMA Style
Blank CU, Wong DJ, Ho TH, Bauer TM, Lee CB, Bene-Tchaleu F, Zhu J, Zhang X, Cha E, Sznol M.
Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors. Current Oncology. 2021; 28(6):5466-5479.
https://doi.org/10.3390/curroncol28060455
Chicago/Turabian Style
Blank, Christian U., Deborah J. Wong, Thai H. Ho, Todd M. Bauer, Carrie B. Lee, Fabiola Bene-Tchaleu, Jing Zhu, Xiaosong Zhang, Edward Cha, and Mario Sznol.
2021. "Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors" Current Oncology 28, no. 6: 5466-5479.
https://doi.org/10.3390/curroncol28060455
APA Style
Blank, C. U., Wong, D. J., Ho, T. H., Bauer, T. M., Lee, C. B., Bene-Tchaleu, F., Zhu, J., Zhang, X., Cha, E., & Sznol, M.
(2021). Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors. Current Oncology, 28(6), 5466-5479.
https://doi.org/10.3390/curroncol28060455
